Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Xencor Inc

XNCR · Nasdaq · CIK 0001326732 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

13 Form 4 transaction lines observed in the same window
5 sales · 8 option, withholding, award, gift or other lines

Last qualifying purchase2024-02-13 · GORMAN KEVIN CHARLES · $1.0K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Feigal EllenDirector
○▼
RANIERI RICHARD JDirector
▼○
Montgomery Alan BruceDirector
▼○
GUSTAFSON KURT ADirector
▼○
GORMAN KEVIN CHARLESDirector
▼○
SIMPSON TODD EDirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 2 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-02-13 · GORMAN KEVIN CHARLES.

Recent Form 4 activity

0Purchases
18Sales
17Other Form 4 lines
25SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING5 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
16,368,875
Previous report
15,751,444
Avg daily volume
1,618,765
Days to cover
10.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2024-02-13GORMAN KEVIN CHARLESPurchase (P)Common Stock53USD 19.12USD 1,013SEC filing ↗

Form 4 evidence

35 transaction lines in the latest 365-day window; 193 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-18Feigal EllenSale (S)Common Stock6,843USD 13.06USD 89,370SEC filing ↗
2026-06-16SIMPSON TODD EAward / grant (A)Common Stock10,302USD 0.00USD 0SEC filing ↗
2026-06-16RANIERI RICHARD JAward / grant (A)Common Stock10,302USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-18Feigal EllenSale (S)Common Stock6,843USD 13.06USD 89,370SEC filing ↗
2026-06-16SIMPSON TODD EAward / grant (A)Common Stock10,302USD 0.00USD 0SEC filing ↗
2026-06-16RANIERI RICHARD JAward / grant (A)Common Stock10,302USD 0.00USD 0SEC filing ↗
2026-06-16Montgomery Alan BruceAward / grant (A)Common Stock10,302USD 0.00USD 0SEC filing ↗
2026-06-16Klencke BarbaraAward / grant (A)Common Stock10,302USD 0.00USD 0SEC filing ↗
2026-06-16GUSTAFSON KURT AAward / grant (A)Common Stock10,302USD 0.00USD 0SEC filing ↗
2026-06-16GORMAN KEVIN CHARLESAward / grant (A)Common Stock10,302USD 0.00USD 0SEC filing ↗
2026-06-16Feigal EllenAward / grant (A)Common Stock10,302USD 0.00USD 0SEC filing ↗
2026-06-16Deshaies Raymond JosephAward / grant (A)Common Stock10,302USD 0.00USD 0SEC filing ↗
2026-06-15RANIERI RICHARD JSale (S)Common Stock5,474USD 12.31USD 67,385SEC filing ↗
2026-06-15Montgomery Alan BruceSale (S)Common Stock5,064USD 12.31USD 62,338SEC filing ↗
2026-06-15GUSTAFSON KURT ASale (S)Common Stock5,474USD 12.31USD 67,385SEC filing ↗
2026-06-15GORMAN KEVIN CHARLESSale (S)Common Stock7,527USD 12.31USD 92,657SEC filing ↗
2026-04-10Cornelissen Bart JanSale (S)Common Stock3,499USD 12.29USD 43,003SEC filing ↗
2026-03-06Eckert CeliaSale (S)Common Stock1,767USD 11.02USD 19,472SEC filing ↗
2026-03-06Desjarlais John RSale (S)Common Stock2,502USD 11.02USD 27,572SEC filing ↗
2026-03-06Dahiyat Bassil ISale (S)Common Stock6,606USD 11.02USD 72,798SEC filing ↗
2026-03-05Eckert CeliaSale (S)Common Stock3,244USD 11.25USD 36,495SEC filing ↗
2026-03-05Desjarlais John RSale (S)Common Stock4,118USD 11.25USD 46,328SEC filing ↗
2026-03-05Dahiyat Bassil ISale (S)Common Stock14,870USD 11.25USD 167,288SEC filing ↗
2026-03-05Cornelissen Bart JanSale (S)Common Stock2,517USD 11.25USD 28,316SEC filing ↗
2026-03-03Eckert CeliaSale (S)Common Stock1,492USD 11.90USD 17,755SEC filing ↗
2026-03-03Desjarlais John RSale (S)Common Stock2,663USD 11.90USD 31,690SEC filing ↗
2026-03-03Dahiyat Bassil ISale (S)Common Stock6,758USD 11.90USD 80,420SEC filing ↗
2026-03-02Eckert CeliaAward / grant (A)Common Stock18,680USD 0.00USD 0SEC filing ↗
2026-03-02Desjarlais John RAward / grant (A)Common Stock24,907USD 0.00USD 0SEC filing ↗
2026-03-02Dahiyat Bassil IAward / grant (A)Common Stock97,291USD 0.00USD 0SEC filing ↗
2026-03-02Cornelissen Bart JanAward / grant (A)Common Stock19,458USD 0.00USD 0SEC filing ↗
2026-01-23Desjarlais John ROption exercise / conversion (M)Common Stock5,322USD 12.51USD 66,578SEC filing ↗
2025-12-22Desjarlais John ROption exercise / conversion (M)Common Stock6,311USD 12.51USD 78,951SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerXNCR
CIK0001326732
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history193 transaction lines from 2020-01-06 to 2026-06-18
1 P purchase lines · 92 S sale lines · 100 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.